Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study

<p>Abstract</p> <p>Background</p> <p>Neutralizing antibodies (NAbs) against Interferon beta (IFNβ) are reported to be associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to quantify the contribution of NAbs to the sub-optimal...

Full description

Bibliographic Details
Main Authors: Cefaro Luca, Bellomi Francesca, Gasperini Claudio, Tomassini Valentina, Sbardella Emilia, Morra Vincenzo, Antonelli Guido, Pozzilli Carlo
Format: Article
Language:English
Published: BMC 2009-10-01
Series:BMC Neurology
Online Access:http://www.biomedcentral.com/1471-2377/9/54

Internet

http://www.biomedcentral.com/1471-2377/9/54

Similar Items